Minomic

Minomic

Minomic is making waves globally with their groundbreaking innovation. With strong collaborations with universities, research institutes, and companies, Minomic boasts a wealth of expertise in oncology.

Their flagship product, MiCheck® Prostate, is an advanced algorithm that combines the results of three serum immunoassays with relevant clinical factors that accurately indicate the likelihood of aggressive prostate cancer.

Minomic is dedicated to developing MiCheck® Prostate as a supplement to other clinical factors and test results. Rather than replacing the judgment and experience of urologists, MiCheck® Prostate aims to assist physicians in making informed decisions about whether a prostate biopsy is necessary for male patients under consideration.

See more here.